Eris Lifesciences Q2 Results
- BSE: 540596
- NSE: ERIS
- ISIN: INE406M01024
- Sector: Biotechnology & Drugs
BSE
1,427.40
14.45 (1.02%)
14.45 (1.02%)Volume1.21 K
Updated: Fri 6 Feb, 2026 | 15:25:49
NSE
1,430.7017.50 (1.24%)
17.50 (1.24%)Volume25.81 K
Updated: Fri 6 Feb, 2026 | 15:30:02
Technical Trends
Long TermConsiders price movement over the last 6 months
Not Available
Short TermConsiders price movement over the last 1-2 weeks
Not Available
- Bearish
- Moderately Bearish
- Neutral
- Moderately Bullish
- Bullish
Insight: Trends unavailable at the moment.
Q2 Results Highlights
- Total Income₹792.41 Cr.(6.91%)
- Operating Profit₹219.13 Cr.(19.07%)
- Profit After Tax₹120.19 Cr.(31.23%)
- Operating Margin27.65%(11.37%)
Note: Comparison is on YoY basis
Quarterly - Eris Lifesciences Q2 Results
*All figures in crores except per share values
| Fiscal Period | Sep 25 | Jun 25 | QoQ Comp | Sep 24 | YoY Comp |
|---|---|---|---|---|---|
| Total Operating Expense | 573.28 | 566.80 | 1.14% | 557.14 | 2.90% |
| Depreciation/ Amortization | 69.08 | 70.51 | -2.03% | 80.48 | -14.17% |
| Operating Income | 219.13 | 206.20 | 6.27% | 184.03 | 19.07% |
| Net Income | 120.19 | 117.99 | 1.86% | 91.59 | 31.23% |
| Other Operating Expenses Total | 164.34 | 167.22 | -1.72% | 164.76 | -0.25% |
| Net Income Before Taxes | 172.67 | 161.10 | 7.18% | 129.11 | 33.74% |
| Total Revenue | 792.41 | 773.00 | 2.51% | 741.17 | 6.91% |
| Selling/ General/ Admin Expenses Total | 137.45 | 144.43 | -4.83% | 125.63 | 9.41% |
| Diluted Normalized EPS | 8.81 | 8.64 | 1.97% | 6.72 | 31.10% |